Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of hepatocellular carcinoma, androgen receptor positive (AR+) triple negative breast cancer, estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer, and AR+ HER2 amplified breast cancer. In addition, it develops Talazoparib, which is in phase II clinical trials for treatment of germline mutated HER2 normal breast cancer; Pidilizumab that is in phase II clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and MDV4463, which is in phase I clinical trials for the treatment of nonalcoholic steatohepatitis. The company has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and license and manufacturing, and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. Medivation, Inc. is headquartered in San Francisco, California. As of September 27, 2016, Medivation, Inc. operates as a subsidiary of Pfizer Inc.